• Fulltext

       

        Click here to view fulltext PDF


      Permanent link:
      https://www.ias.ac.in/article/fulltext/jbsc/040/01/0079-0090

    • Keywords

       

      Classical swine fever (CSF); E2; human adenovirus; invasin; vaccine

    • Abstract

       

      The use of adenovirus vector-based vaccines is a promising approach for generating antigen-specific immune responses. Improving vaccine potency is necessary in other approaches to address their inadequate protection for the majority of infectious diseases. This study is the first to reconstruct a recombinant replication-defective human adenovirus co-expressing E2 and invasin C-terminal (InvC) glycoproteins (rAd-E2-InvC). rAd-E2-InvC with 2×106 TCID50 was intramuscularly administered two times to CSFV-free pigs at 14 day intervals. No adverse clinical reactions were observed in any of the pigs after the vaccination. The CSFV E2-specific antibody titer was significantly higher in the rAd-E2-InvC group than that in the rAdV-E2 group as measured by NPLA and blocking ELISA. Pigs immunized with rAd-E2-InvC were completely protected against lethal challenge. Neither CSFV RNA nor pathological changes were detected in the tissues after CSFV challenge. These results demonstrate that rAd-E2-InvC could be an alternative to the existing CSF vaccine. Moreover, InvC that acts as an adjuvant could enhance the immunogenicity of rAdV-E2 and induce high CSFV E2-specific antibody titer and protection level.

    • Author Affiliations

       

      Helin Li1 Pengbo Ning1 Zhi Lin1 Wulong Liang1 Kai Kang1 Lei He2 Yanming Zhang1

      1. College of Veterinary Medicine, Northwest A & F University, Yangling 712100, Shaanxi, China
      2. College of Animal Science & Technology, Henan University of Science and Technology, Luoyang 471023, Henan, China
    • Dates

       
  • Journal of Biosciences | News

© 2017-2019 Indian Academy of Sciences, Bengaluru.